The COVID-19 pandemic: a catalyst to improve clinical trials

Prakriti Gaba; Deepak L Bhatt

doi:10.1038/s41569-020-00439-7

The COVID-19 pandemic: a catalyst to improve clinical trials

Nat Rev Cardiol. 2020 Nov;17(11):673-675. doi: 10.1038/s41569-020-00439-7.

Authors

Prakriti Gaba¹, Deepak L Bhatt²

Affiliations

¹ Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
² Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. dlbhattmd@post.harvard.edu.

Abstract

The COVID-19 pandemic has provided the vital stepping stones to improve how clinical trials are conducted. We provide an overview of the major changes to the clinical trial process instigated by the pandemic and suggest ways to make these changes sustainable.

MeSH terms

COVID-19
Clinical Trials as Topic / standards*
Coronavirus Infections / epidemiology*
Humans
Informed Consent / standards
Pandemics*
Patient Selection
Pneumonia, Viral / epidemiology*
Quality Improvement
Telemedicine / standards